
Neuro-Oncology: The Podcast
154 episodes — Page 3 of 4
Objective response rate targets for recurrent glioblastoma clinical trials
Dr. Maya Graham interviews Drs. Benjamin Ellingston and Timothy Cloughesy about their recently published manuscript entitled: "Objective response rate (ORR) targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival", published online in Neuro-Oncology in January 2023. Read Paper
Mitotic count prognostic significance in IDH-mutant astrocytoma in the molecular era
Dr. Iyad Alnahhas interviews Dr. Max Kros about his and his team's recent manuscript entitled: "Mitotic count is prognostic in IDH-mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trials 26053 and EORTC 22033-26033", published online in Neuro-Oncology in December 2022. Read Paper
Palliative care in neuro-oncology
Dr. Iyad Alnahhas interviews Drs. Tobias Walbert and Johan Koekkoek about their recent manuscript entitled "Palliative care and end-of-life care in adults with malignant brain tumors", published online in Neuro-Oncology in October 2022 Read Paper
Nivolumab in MGMT methylated GBM
Description: Dr. Jasmin Jo interviews Dr. Michael Lim about his and his team's recent manuscript entitled: "Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter", published online in Neuro-Oncology in November 2022.
IDH mutant gliomas; SNO consensus Review
Description: Dr. Ankush Bhatia interviews Drs. Julie Miller, Nicolas Gonzalez Castro, Samuel McBrayer and Patrick Wen about their recent manuscript, entitled: "Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions", published online in Neuro-Oncology in October 2022. Full Report
DNA methylation subclass and extent of GBM resection
Dr. Evan Noch interviews Drs. Richard Drexler and Franz Ricklefs about their recent manuscript entitled: "DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients", published online in Neuro-Oncology in July 2022. Full Report
Pre-operative [11C]methionine PET for low-grade glioma
Description: Dr. Maya Graham interviews Drs. Gaia Ninatti and Martina Sollini about their recent manuscript entitled: "Pre-operative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas", published online in Neuro-Oncology in September 2022. Full Report
The role of T lymphocytes in the glioma pathobiology
Dr. Iyad Alnahhas interviews Dr. David Gutmann about the review entitled "T lymphocytes as dynamic regulators of glioma pathobiology", published online in Neuro-Oncology in March 2022. Read paper
CDKN2A homozygous deletion in IDH mutant astrocytoma
Dr. Evan Noch interviews Drs. Shannon Fortin Ensign and Sani Kizilbash about their recent paper in Neuro-Oncology entitled: "Translational significance of CDKN2A/B homozygous deletion in IDH mutant astrocytoma", published online in Neuro-Oncology in August 2022 Full Report
EGFR: the lazarus target in glioblastom
Dr. Maya Graham interviews Drs. Benjamin Lin, David Nathanson, Frank Furnari and Ryan Miller about their recent manuscript entitled: "EGFR, the Lazarus target for precision oncology in glioblastoma", published online in Neuro-Oncology in September 2022.
Brain metastases; a SNO consensus review: Part 2
In this second of two episodes, Dr. Iyad Alnahhas interviews Drs. Ross Camidge, Michael Davis, Nancy Lin and Ayal Aizer about the recent editorial review entitled: "Brain Metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions", published online in Neuro-Oncology in June 2022. Full Report
Brain metastases; a SNO consensus review: Part 1
In this first of two episodes, Dr. Iyad Alnahhas interviews Drs. Ayal Aizer, Eudocia Lee and Veronica Chiang about the recent editorial review entitled: "Brain Metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions", published online in Neuro-Oncology in June 2022. Full Report
Pediatric IDH mutant gliomas
Dr. Iyad Alnahhas interviews Drs. Jennifer Cotter and Kee Kiat Yeo about their recent paper entitled: ""Multi-institutional study of the frequency, genomic landscape and outcome of IDH-mutant glioma in pediatrics", published online in Neuro-Oncology in May 2022. Full Article
Low-risk meningioma: Outcomes from NRG 0539
Dr. Jasmin Jo interviews Dr. Leland Rogers about his and his team's recent manuscript entitled: "Low-risk meningioma: initial outcomes from NRG Oncology/RTOG 0539", published online in Neuro-Oncology in June 2022 Full Article
Selumetinib in children with NF1 and plexiform neurofibroma
Dr.Iyad Alnahhas interviews Drs. Andrea Gross and Brigitte Widemann about their manuscript entitled "Selumetinib in Children with Neurofibromatosis Type 1 and Asymptomatic Inoperable Plexiform Neurofibroma at Risk for Developing Tumor-Related Morbidity", published online in Neuro-Oncology in April 2022. Full Article
Targeted therapy for BRAF-mutant pediatric glioma
Dr. Evan Noch interviews Drs. Kee Kiat Yeo and Matthias Karajannis about their recent manuscript entitled: "Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high grade glioma", published online in Neuro-Oncology in April 2022. Link to article
Early/evolving IDH wild-type glioblastoma
Description: Dr. Maya Graham interviews Dr. David Solomon about his and his team's recent manuscript entitled: "Prospective genomically-guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes", published online in Neuro-Oncology in April 2022. Read Article
PI3K signaling in IDH mutant gliomas
Dr. Evan Noch interviews Dr. Joanna Phillips about her and her team manuscript entitled: "PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications", published online in Neuro-Oncology in March 2022.
Cell-free DNA from CSF in pediatric, adolescent and young adult patients
Dr. Iyad Alnahhas interviews Dr. Matthias Karajannis about his and his team's recent manuscript entitled: "Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult (AYA) brain tumor patients", published in Neuro-Oncology in February 2022
Molecular determinants of neurocognitive deficits in glioma
Dr. Ankush Bhatia interviews Dr. Emma van Kessel about her and her team's recent manuscript entitled "Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma", published online in Neuro-Oncology in February 2022. Full Report
H3K27M cell-free tumor DNA tracking in response to ONC201 treatment for diffuse midline glioma
Dr. Iyad Alnahhas interviews Dr. Carl Koschmann about his and his team's recent manuscript entitled: "Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma" published online in Neuro-Oncology in February 2022. Read the Study
Clinical trial accrual for women and minorities in neuro-oncology
Dr. Rachna Malani interviews Dr. Hervey-Jumper about his and his team's recent manuscript entitled "A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH revitalization act", published online in Neuro-Oncology in January 2022. See study here
The clinical utility of next generation sequencing for IDHwt glioblastoma
Dr. Evan Noch interviews Dr. Mary Jane Lim-Fat about her and her team's recent manuscript entitled: "Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making", published online in Neuro-Oncology in December 2021.
Trabectedin for recurrent grade 2 or 3 meningiomas
Dr. Iyad Alnahhas interviews Dr. Matthias Preusser about the recent manuscript entitled: "Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG)", published online in Neuro-Oncology in October 2021.
Glioblastoma cell heterogeneity and plasticity
Dr. Iyad Alnahhas interviews Drs. Simone Niclou and Anna Golebiewska about their recent manuscript, entitled: 'Cancer Cell Heterogeneity and Plasticity: A Paradigm Shift in Glioblastoma', published online in Neuro-Oncology in December 2021.
Moleculary integrated grading for meningioma
Dr. Nicholas Butowski interviews Drs. Sandro Santagata and Wenya Linda Bi about their recent manuscript entitled: "A molecularly integrated grade for meningioma", published online in Neuro-Oncology in September 2021.
BOLD fMRI in IDH mutant gliomas
Dr. Ankush Bhatia interviews Dr. Jack Grinband about his recent manuscript entitled "BOLD Asynchrony Elucidates Tumor Burden in IDH-Mutated Gliomas", published online in Neuro-Oncology in July 2021
Glioblastoma subtypes and response to Dasatinib
Dr. Evan Noch interviews Drs. Emma Phillips and Violaine Goidts about their recent manuscript entitled "A Novel Patient Stratification Strategy to Enhance the Therapeutic Efficacy of Dasatinib in Glioblastoma", published online in Neuro-Oncology in July 2021.
Resection for recurrent brain metastases
Dr. Iyad Alnahhas interviews Dr. Alexander Hulsbergen about his and his team's recent manuscript entitled: "Neurosurgical resection for locally recurrent brain metastases", published online in Neuro-Oncology in July 2021.
Incidental Meningiomas
Dr. Jasmin Jo interviews Dr. Jason Sheehan about the recent manuscript entitled: "A Multicenter Matched Cohort Analysis of Incidental Meningioma Progression During Active Surveillance or After Active Stereotactic Radiosurgery: The IMPASSE Study", published online in Neuro-Oncology in June 2021.
Immunosuppression in IDH mutant gliomas
Dr. Maya Graham interviews Dr. Nduka Amankulor about the recent manuscript entitled: "Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles" published online in Neuro-Oncology in July 2021.
Immunotherapy for melanoma brain metastases
Dr. Ankush Bhatia interviews Dr. Hussein Tawbi about his and his team's recent manuscript entitled "Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases: Checkmate-204", published online in Neuro-Oncology in April 2021.
DNA methylation profiles within the CATNON trial
Dr. Iyad Alnahhas interviews Dr. Pim French about his and his team recent manuscript entitled: "Prognostic significance of genome-wide DNA methylation profiles within the randomised, phase 3, EORTC CATNON trial on non-1p19q deleted anaplastic glioma", published online in Neuro-Oncology in April 2021
18F FET PET in childhood CNS tumors
Description: Dr. Maya Graham interviews Dr. Lisbeth Marner about her recent manuscript "" Diagnostic accuracy and clinical impact of 18F FET PET in childhood CNS tumors" " published online in April 2021 in Neuro-Oncology.
Checkpoint blockade in atypical meningiomas
Description: Dr. Nicholas Butowski interviews Dr. David Reardon about his recent manuscript "Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results", published online in Neuro-Oncology in May 2021.
Molecular signatures of glioma causation
Dr. Evan Noch interviews Dr. Elizabeth Claus about her recent manuscript entitled: "Environmental and sex-specific molecular signatures of glioma causation" published online in Neuro-Oncology in May 2021.
Testing methods for MGMT promoter methylation
Dr. Iyad Alnahhas interviews Dr. Kathreena Kurian about her and her team's recent manuscript entitled: "MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Review", published online in Neuro-Oncology in April 2021.
Temozolomide-induced hypermutation in IDH-mutant low-grade gliomas
Dr. Maya Graham interviews Dr. Nancy Ann Oberheim Bush about her and her team's paper entitled " Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas" published online in Neuro-Oncology in April 2021
Posterior fossa syndrome
Dr. Iyad Alnahhas interviews Dr. Raja Khan about their recent manuscript entitled "Clinical features, neurologic recovery, and risk factors of post-operative posterior fossa syndrome and delayed recovery: a prospective study", published online in April 2021 in Neuro-Oncology.
Loss of H3K27me3 in meningiomas
Dr. Evan Noch interviews Drs. Farshad Nassiri and Justin Wang from the team of Dr. Gelareh Zadeh about their recently published paper entitled "Loss of H3K27me3 in meningiomas" published online in Neuro-Oncology in May 2021.
Loss of H3K27me3 in the Tübingen meningioma cohort
Dr. Maya Graham interviews Drs. Ghazaleh Tabatabai and Felix Behling about their paper entitled "H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort" published online in Neuro-Oncology in December 2020.
A prospective phase II randomized trial of proton radiotherapy vs intensity modulated radiotherapy for patients with newly diagnosed GBM
Dr. Jasmin Jo interviews Dr. Caroline Chung about her paper: "A prospective phase II randomized trial of proton radiotherapy vs intensity modulated radiotherapy for patients with newly diagnosed GBM" published online in Neuro-Oncology in Feb 2021.
Brain radiotherapy and decline in fine motor skills
Dr. Iyad Alnahhas interviews Dr. Jona Hattangadi-Gluth and Ms. Mia Salans about their recently published manuscript entitled: "Longitudinal change in fine motor skills after brain radiotherapy and in vivo imaging biomarkers associated with decline" published online in February 2021 in Neuro-Oncology.
A serum based DNA methylation assay to detect gliomas
Dr. Iyad Alnahhas interviews Dr. Houton Noushmehr about his recent paper "A serum-based DNA methylation assay provides accurate detection of glioma", published online in Feb 2021 in Neuro-Oncology
Ep 9PTEN deficiency and proteosome addiction in glioblastoma
Dr. Evan Noch interviews Drs. Frank Furnari and Jorge Benitez about their recent paper: "PTEN deficiency leads to proteosome addiction, a novel vulnerability in glioblastoma" published online in Neuro-Oncology in January, 2021.
Ep 8Cold-Inducible RNA-Binding Protein expression and recurrence of brain metastases
Dr. Alireza Mansouri interviews Dr. Matthew Dankner about his recent paper "Invasive growth associated with Cold-Inducible RNA-Binding Protein expression drives recurrence of surgically resected brain metastases" published online in Neuro-Oncology in January, 2021.
Ep 7The incidence of brain metastases among patients with metastatic breast cancer
Dr. Iyad Alnahhas interviews Dr. Katarzyna Jerzak about her recent paper "The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis", published online in Neuro-Oncology in December, 2020.
Ep 6Epidemiology of Brainstem High-Grade Gliomas in Children and Adolescents in the United States, 2000-2017
Dr. Evan Noch interviews Dr. Jill Barnholtz-Sloan about her recent paper "Epidemiology of Brainstem High-Grade Gliomas in Children and Adolescents in the United States, 2000-2017" published online in Neuro-Oncology in December 2020.
Ep 5A large longitudinal study of patients with Neurofibromatosis Type 2.
Dr. Iyad Alnahhas interviews Dr. Gareth Evans about his recent paper in Neuro-Oncology entitled: "Disease course of Neurofibromatosis Type 2; a 30-year follow-up study of 353 patients seen at a single institution
Ep 4Vorinostat and bevacizumab for recurrent glioblastoma
Dr. Iyad Alnahhas interviews Drs. Vinay Puduvalli and Ying Yuan about their paper "A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma" published in Neuro-Oncology in March 2020